Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
US11312718B2 · kind B2 · utility
0Cited by
275References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 3, 2020 |
| Grant date | Apr 26, 2022 |
| Priority date | — |
| Expiry date | Jan 3, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.